*Alex is the first beneficiary of a trial on a new drug that uses precision oncology, which targets the genetic make-up of tumour with the aim of blocking it from multiplying. If successful, the drug will revolutionise cancer treatment globally.

The goal of the study is to find out if the new drug can be used in the treatment for all cancers.